Related Experiment Video

Updated: Jul 15, 2026

Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

Application since 1980 of antihypertensive agents to treat pediatric disease

A B Gruskin1, S Dabbagh, L E Fleishmann

  • 1Wayne State University School of Medicine, Department of Pediatrics, Detroit, MI 48201.

Journal of Human Hypertension
|May 1, 1994
PubMed

Insights

Antihypertensive agents improve blood pressure control in children with secondary hypertension. However, their effectiveness for chronic primary hypertension in children requires further research. Converting enzyme inhibitors may slow kidney function decline.

Area of Science:

  • Pediatric Nephrology
  • Cardiovascular Pharmacology

Background:

  • Antihypertensive treatment strategies have evolved since 1980.
  • Hypertension in children necessitates specific therapeutic approaches.

Purpose of the Study:

  • To review clinical studies on antihypertensive agents in children beyond the newborn period.
  • To discuss the role of these agents in secondary and primary hypertension.
  • To explore adult treatment protocols applicable to pediatric hypertension.

Main Methods:

  • Literature review of clinical studies.
  • Analysis of antihypertensive agent efficacy in pediatric populations.
  • Examination of treatment protocols for hypertension.

Main Results:

  • Converting enzyme inhibitors and calcium channel blockers enhance blood pressure control in secondary hypertension.
  • The efficacy of chronic antihypertensive treatment for primary hypertension in children is not yet established.
  • Preliminary data suggest converting enzyme inhibitors may mitigate renal function decline in progressive renal diseases.

Conclusions:

  • Antihypertensive agents are effective for secondary hypertension in children.
  • Further research is needed to clarify the role of these agents in primary pediatric hypertension.
  • Converting enzyme inhibitors show promise in managing renal complications.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...